Highly susceptible SARS-CoV-2 model in CAG promoter-driven hACE2-transgenic mice

Masamitsu N Asaka,Daichi Utsumi,Haruhiko Kamada,Satoshi Nagata,Yutaka Nakachi,Tomokazu Yamaguchi,Yoshihiro Kawaoka,Keiji Kuba,Yasuhiro Yasutomi
DOI: https://doi.org/10.1172/jci.insight.152529
IF: 9.4958
2021-10-08
JCI Insight
Abstract:COVID-19, caused by SARS-CoV-2, has spread worldwide with dire consequences. To urgently investigate the pathogenicity of COVID-19 and develop vaccines and therapeutics, animal models that are highly susceptible to SARS-CoV-2 infection are needed. In the present study, we established an animal model highly susceptible to SARS-CoV-2 via the intratracheal tract infection in CAG promoter-driven human angiotensin-converting enzyme 2-transgenic (CAG-hACE2) mice. The CAG-hACE2 mice showed several severe symptoms of SARS-CoV-2 infection, with definitive weight loss and subsequent death. Acute lung injury with elevated cytokine and chemokine levels was observed at an early stage of infection in CAG-hACE2 mice infected with SARS-CoV-2. Analysis of the hACE2 gene in CAG-hACE2 mice revealed that more than 15 copies of hACE2 genes were integrated in tandem into the mouse genome, supporting the high susceptibility to SARS-CoV-2. In the developed model, immunization with viral antigen or injection of plasma from immunized mice prevented body weight loss and lethality due to infection with SARS-CoV-2. These results indicate that a highly susceptible model of SARS-CoV-2 infection in CAG-hACE2 mice via the intratracheal tract is suitable for evaluating vaccines and therapeutic medicines.
What problem does this paper attempt to address?